Radiolabelled regulatory peptides for imaging and therapy

Area of Science:

• Nuclear medicine
• Radiopharmaceutical chemistry
• Oncology

Background:

• Regulatory peptides and their receptors are key targets in cancer diagnostics and therapeutics.
• Radiolabeled peptides offer high affinity and specificity for receptor-mediated targeting.
• Receptor expression varies across different tissues and tumors, influencing targeting efficacy.

Purpose of the Study:

• To review the application of regulatory peptides radiolabeled with specific radionuclides for cancer imaging and therapy.
• To discuss the current research status, limitations, and future perspectives of these radiopharmaceuticals.
• To highlight somatostatin receptor-mediated imaging and therapy as a primary focus, including new developments.

Main Methods:

• Review of scientific literature on radiolabeled peptides for oncology.
• Focus on peptides labeled with Gallium-67/68 (Ga), Yttrium-90 (Y), Indium-111 (In), and Lutetium-177 (Lu).
• Inclusion of basic science, preclinical, and clinical aspects, with emphasis on somatostatin receptor applications.

Main Results:

• Radiolabeled peptides are effective tools for imaging and therapy of receptor-expressing malignancies.
• Somatostatin receptor-targeted agents show significant promise in clinical applications.
• Ongoing research focuses on novel analogues, chelators, and radionuclides to enhance efficacy.

Conclusions:

• Radiolabeled peptides, particularly somatostatin analogues, represent a significant advancement in personalized cancer medicine.
• Further development of new radiolabeling strategies and radionuclide combinations is crucial for expanding their therapeutic and diagnostic potential.
• These agents offer a promising avenue for targeted cancer imaging and radiotherapy.